Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Next Previous
Trial Profile

A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; Itacitinib (Primary) ; Parsaclisib (Primary) ; Ruxolitinib (Primary)
  • Indications B-cell leukaemia; B-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Incyte Corporation

Most Recent Events

  • 01 Nov 2024 Status changed from recruiting to active, no longer recruiting.
  • 22 Oct 2024 Planned End Date changed from 30 Sep 2024 to 30 Sep 2027.
  • 22 Oct 2024 Planned primary completion date changed from 30 Sep 2024 to 30 Sep 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top